Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study

Data are scarce regarding both the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing immune cell therapy; thus, we prospectively evaluated these two domains in patients receiving this vaccine after allogeneic hematopoietic cell transplantation (HCT; n = 66) or af...

Descripción completa

Detalles Bibliográficos
Autores principales: Ram, Ron, Hagin, David, Kikozashvilli, Nino, Freund, Tal, Amit, Odelia, Bar-On, Yael, Beyar-Katz, Ofrat, Shefer, Gabi, Moshiashvili, Miguel Morales, Karni, Chen, Gold, Ronit, Kay, Sigi, Glait-Santar, Chen, Eshel, Rinat, Perry, Chava, Avivi, Irit, Apel, Arie, Benyamini, Noam, Shasha, David, Ben-Ami, Ronen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2021
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242200/
https://www.ncbi.nlm.nih.gov/pubmed/34214738
http://dx.doi.org/10.1016/j.jtct.2021.06.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242200/
https://www.ncbi.nlm.nih.gov/pubmed/34214738
http://dx.doi.org/10.1016/j.jtct.2021.06.024

Ejemplares similares